Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, imipenem / cilastatin + relebactam (Recarbrio®) cannot be endorsed for use within NHS Wales for the treatment of hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP), in adults and the treatment of bacteraemia that occurs in association with, or is suspected to be associated with HAP or VAP, in adults. |
||
|
||
Medicine details |
||
| Medicine name | imipenem / cilastatin + relebactam (Recarbrio®) | |
| Formulation | 500 mg/500 mg/250 mg powder for solution for infusion | |
| Reference number | 4800 | |
| Indication | Treatment of hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP), in adults and the treatment of bacteraemia that occurs in association with, or is suspected to be associated with HAP or VAP, in adults |
|
| Company | Merck Sharp & Dohme Ltd | |
| BNF chapter | Infections | |
| Assessment type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 24/05/2021 | |